The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL‐17A inhibition in psoriasis
Open accessAbstract
The response of psoriasis to antibodies targeting the interleukin (IL)‐23/IL‐17A pathway suggests a prominent role of T‐helper type‐17 (Th17) cells in this disease. We examined the clinical and immunological response patterns of 100 subjects with moderate‐to‐severe psoriasis receiving 3 different intravenous dosing regimens of the anti‐IL‐17A antibody secukinumab (1 × 3 mg/kg or 1 × 10 mg/kg on Day 1, or 3 × 10 mg/kg on Days 1, 15 and 29) or placebo in a phase 2 trial. Baseline biopsies revealed typical features of active psoriasis, including epidermal accumulation of neutrophils and formation of microabscesses in >60% of cases. Neutrophils were the numerically largest fraction of infiltrating cells containing IL‐17 and may store the cytokine preformed, as IL‐17A mRNA was not detectable in neutrophils isolated from active plaques. Significant clinical responses to secukinumab were observed 2 weeks after a single infusion, associated with extensive clearance of cutaneous neutrophils parallel to the normalization of keratinocyte abnormalities and reduction of IL‐17‐inducible neutrophil chemoattractants (e.g. CXCL 1, CXCL 8); effects on numbers of T cells and CD 11c‐positive dendritic cells were more delayed. Histological and immunological improvements were generally dose dependent and not observed in the placebo group. In the lowest‐dose group, a recurrence of neutrophils was seen in some subjects at Week 12; these subjects relapsed faster than those without microabscesses. Our findings are indicative of a neutrophil–keratinocyte axis in psoriasis that may involve neutrophil‐derived IL‐17 and is an early target of IL‐17A‐directed therapies such as secukinumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Secukinumab in plaque psoriasis—results of two phase 3 trials
Langley, R. G., Elewski, B. E., Lebwohl, M., Reich, K., Griffiths, C. E. M., Papp, K., Puig, L., Nakagawa, H., Spelman, L., Sigurgeirsson, B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314258 · Cited by 1,997
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Griffin, G. K., Newton, G., Tarrio, M. L., Bu, D.-X., Maganto-Garcia, E., Azcutia, V., Alcaide, P., Grabie, N., Luscinskas, F. W., Croce, K. J., et al. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1200385 · Cited by 364
Cited by
Crosstalk: keratinocytes and immune cells in psoriasis
Kamata, M., & Tada, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1286344 · Cited by 110
Role of Neutrophils in Psoriasis
Wang, W.-M., & Jin, H.-Z. (2020) · Journal of Immunology Research · doi:10.1155/2020/3709749 · Cited by 77
Ma, Y., Liu, Y., Zhong, Y., Li, X., Xu, Y., Chen, L., Gong, L., Huang, H., Chen, X., He, Y., et al. (2024) · British Journal of Pharmacology · doi:10.1111/bph.17349 · Cited by 14
Metadata
- Authors
- Reich, K., Papp, K. A., Matheson, R. T., Tu, J. H., Bissonnette, R., Bourcier, M., Gratton, D., Kunynetz, R. A., Poulin, Y., Rosoph, L. A., Stingl, G., Bauer, W. M., Salter, J. M., Falk, T. M., Blödorn‐Schlicht, N. A., Hueber, W., Sommer, U., Schumacher, M. M., Peters, T., Kriehuber, E., Lee, D. M., Wieczorek, G. A., Kolbinger, F., & Bleul, C. C.
- Venue
- Experimental Dermatology
- Publisher
- Wiley
- Published
- 2015-05-08
- Volume
- 24
- Issue
- 7
- Pages
- 529-535
- ISSN
- 0906-6705 (ISSN-L)
- 1600-0625
- OpenAlex
- W2029128580
- Cited by
- 204
- References
- 3
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL‐17A inhibition in psoriasis. https://app.cochat.ai/papers/10.1111/exd.12710
- The paper
- Reich, K., Papp, K. A., Matheson, R. T., Tu, J. H., Bissonnette, R., Bourcier, M., Gratton, D., Kunynetz, R. A., Poulin, Y., Rosoph, L. A., Stingl, G., Bauer, W. M., Salter, J. M., Falk, T. M., Blödorn‐Schlicht, N. A., Hueber, W., Sommer, U., Schumacher, M. M., Peters, T., . . . Bleul, C. C. (2015). Evidence that a neutrophil–keratinocyte crosstalk is an early target of IL‐17A inhibition in psoriasis. Experimental Dermatology. https://doi.org/10.1111/exd.12710
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.